AntiBio Cancer Research Results

AntiBio, Antibiotic/Antimicrobial activity: Click to Expand ⟱
Source:
Type:

Antibiotic / antimicrobial activity: The ability of a substance to suppress or kill microorganisms, especially bacteria, by disrupting microbial survival, growth, biofilm formation, cell-wall integrity, membrane function, protein synthesis, nucleic-acid synthesis, quorum sensing, or virulence.

Natural Products that might have antimicrobial properties

Natural supplement or product Principal constituents Potential antimicrobial activity Evidence assessment Reference
Garlic
Allium sativum		 Allicin, ajoene and diallyl sulfides Antibacterial and antifungal activity, with some antiviral and antiparasitic effects reported in laboratory studies. Extensive laboratory evidence, but insufficient clinical evidence to use garlic as a treatment for established infections. Tesfaye A. Revealing the therapeutic uses of garlic and its potential for drug discovery. Scientific review.
Berberine Berberine isoquinoline alkaloid May damage bacterial membranes, inhibit efflux pumps, interfere with nucleic-acid and protein synthesis, and inhibit biofilm formation. Strong preclinical evidence and limited indication-specific clinical evidence. Poor oral bioavailability and drug interactions limit its use as a general antimicrobial. Berberine as a therapeutic alkaloid against ESKAPE and multidrug-resistant bacteria: a comprehensive review.
Cranberry extract
Vaccinium macrocarpon		 A-type proanthocyanidins Primarily reduces adhesion of uropathogenic bacteria, particularly Escherichia coli, to urinary epithelial cells. May reduce recurrent urinary tract infections in selected populations. It is preventive rather than a reliable treatment for an active UTI. National Center for Complementary and Integrative Health: Cranberry—Usefulness and Safety.
Probiotics
Lactobacillus, Bifidobacterium and Saccharomyces boulardii 		Live microorganisms; effects are strain-specific Competitive exclusion of pathogens, production of bacteriocins, inhibition of pathogen adhesion and restoration of microbiome function. Some human evidence for antibiotic-associated diarrhea and selected gastrointestinal or vaginal indications. Results cannot be generalized from one strain to another. NIH Office of Dietary Supplements: Probiotics—Health Professional Fact Sheet.
Medical-grade honey / Manuka honey Methylglyoxal, hydrogen peroxide, defensin-1, organic acids and high osmolarity Broad topical antibacterial and antibiofilm activity; also supports autolytic debridement and wound healing. Clinically relevant primarily as a standardized, medical-grade topical wound product. Ordinary food honey is not equivalent. Jull AB et al. Honey as a topical treatment for wounds. Cochrane systematic review.
Oregano oil
Origanum vulgare		 Carvacrol and thymol Antibacterial, antifungal and antibiofilm activity, largely through disruption of microbial membranes. Strong laboratory activity, but inadequate human evidence for oral treatment of infections. Concentrated oil can cause irritation. Chemical composition, biological activity and potential uses of oregano and oregano essential oil: a review.
Thyme
Thymus vulgaris		 Thymol and carvacrol Antibacterial, antifungal and antibiofilm activity through membrane damage and altered microbial permeability. Better established as a constituent of topical antiseptic and oral-care formulations than as an oral treatment for systemic infection. PubMed literature: thyme, thymol and antimicrobial activity.
Tea tree oil
Melaleuca alternifolia		 Terpinen-4-ol and related monoterpenes Topical antibacterial and antifungal activity with some antiviral laboratory activity. Some clinical evidence for topical acne and fungal skin conditions. Tea tree oil is toxic when swallowed and may cause contact dermatitis. Carson CF et al. Melaleuca alternifolia oil: a review of antimicrobial and other medicinal properties.
Echinacea
Echinacea species		 Alkamides, caffeic-acid derivatives, polysaccharides and glycoproteins Primarily immunomodulatory; relatively weak and inconsistent direct antimicrobial activity. Evidence for preventing or shortening respiratory infections is inconsistent and preparation-dependent. National Center for Complementary and Integrative Health: Echinacea—Usefulness and Safety.
Elderberry
Sambucus nigra		 Anthocyanins, flavonols and phenolic acids Antiviral effects have been reported in cell-culture and preclinical studies, including interference with viral entry or replication. Small human trials have examined respiratory symptoms, but evidence remains insufficient to establish treatment of influenza or other viral infections. National Center for Complementary and Integrative Health: Elderberry.
Curcumin / turmeric
Curcuma longa		 Curcumin and related curcuminoids Antibacterial, antifungal, antiviral and antibiofilm activity through multiple membrane, enzyme and signalling effects. Predominantly laboratory evidence. Poor aqueous solubility and low systemic bioavailability are major clinical limitations. Moghadamtousi SZ et al. A review on antibacterial, antiviral and antifungal activity of curcumin.
Ginger
Zingiber officinale		 Gingerols, shogaols and zingerone Antibacterial and antifungal activity, including possible inhibition of microbial adhesion and biofilm formation. Primarily laboratory evidence; there is little direct clinical evidence that ginger supplements treat infections. PubMed literature: ginger, gingerols and antimicrobial activity.
Clove
Syzygium aromaticum		 Eugenol and eugenyl acetate Antibacterial, antifungal and local antiseptic activity, principally through membrane and protein disruption. Relevant mainly to topical, food-preservation and dental applications. Evidence for systemic infection treatment is insufficient. PubMed literature: clove, eugenol and antimicrobial activity.
Cinnamon
Cinnamomum species		 Cinnamaldehyde, eugenol and cinnamic acid derivatives Antibacterial, antifungal and antibiofilm activity; may alter microbial membranes and quorum-sensing pathways. Predominantly laboratory evidence. Cassia cinnamon can contribute substantial coumarin exposure when consumed in concentrated amounts. PubMed literature: cinnamon, cinnamaldehyde and antimicrobial activity.
Neem
Azadirachta indica		 Nimbidin, nimbin, nimbolide, azadirachtin and other limonoids Antibacterial, antifungal, antiparasitic and antibiofilm effects have been reported. Some topical and dental research exists, but systemic clinical evidence is inadequate. Oral neem preparations have important safety concerns. PubMed literature: Azadirachta indica and antimicrobial activity.
Black seed
Nigella sativa		 Thymoquinone, thymohydroquinone and related volatile compounds Antibacterial, antifungal, antiparasitic and possible antiviral activity. Considerable laboratory research but limited, heterogeneous clinical evidence for infectious diseases. PubMed literature: Nigella sativa, thymoquinone and antimicrobial activity.
Green tea extract
Camellia sinensis		 Epigallocatechin gallate (EGCG) and other catechins Antibacterial, antiviral and antibiofilm activity; may damage membranes, inhibit microbial enzymes and enhance some antibiotics. Some localized oral-health evidence, but limited evidence for treating systemic infections. Concentrated extracts may cause liver injury in susceptible individuals. PubMed literature: EGCG, green tea and antimicrobial activity.
Licorice root
Glycyrrhiza species		 Glycyrrhizin, glycyrrhetinic acid, liquiritigenin and other flavonoids Antiviral, antibacterial and antifungal effects have been reported in laboratory and preclinical studies. Limited clinical antimicrobial evidence. Glycyrrhizin can cause hypertension, hypokalemia, fluid retention and clinically important drug interactions. National Center for Complementary and Integrative Health: Licorice Root.
Andrographis
Andrographis paniculata		 Andrographolide and related diterpenoid lactones Immunomodulatory, anti-inflammatory and possible antiviral or antibacterial activity. Some evidence for modest symptom reduction in uncomplicated respiratory infections, but this does not establish direct pathogen eradication. PubMed literature: Andrographis and respiratory infections.
Pelargonium sidoides Proanthocyanidins, phenolic acids and oxygenated coumarin derivatives Possible antiviral, antibacterial anti-adhesive and immunomodulatory activity. Some human evidence for modest symptom improvement in acute bronchitis and selected respiratory infections. It is not a substitute for antibiotics when bacterial treatment is indicated. Timmer A et al. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane systematic review.
Monolaurin
Glycerol monolaurate		 Monolaurin, a monoester derived from lauric acid May disrupt lipid membranes and interfere with signalling or virulence in certain bacteria and enveloped viruses. Predominantly laboratory and animal evidence. There is insufficient clinical evidence to recommend oral monolaurin for infections. PubMed literature: glycerol monolaurate and antimicrobial activity.
Caprylic acid Octanoic acid, an eight-carbon medium-chain fatty acid Antifungal and membrane-disrupting activity, particularly against Candida species, has been reported in vitro. Insufficient human evidence for treating candidiasis or systemic fungal infection. Marketing claims commonly exceed the evidence. PubMed literature: caprylic acid and Candida.
Olive leaf extract
Olea europaea		 Oleuropein, hydroxytyrosol and elenolic-acid derivatives Antibacterial, antiviral and antifungal activity has been observed in laboratory studies. Preliminary evidence only; clinical trials have not established it as a treatment for infectious disease. PubMed literature: olive leaf, oleuropein and antimicrobial activity.
Goldenseal
Hydrastis canadensis		 Hydrastine, canadine and berberine Extracts and individual alkaloids show antibacterial activity in laboratory studies. There is no good clinical evidence that goldenseal treats human infections. Product composition, absorption and drug interactions are important limitations. National Center for Complementary and Integrative Health: Goldenseal.
Sweet wormwood / artemisinin
Artemisia annua 		Artemisinin and related sesquiterpene lactones Artemisinin derivatives are potent antimalarial agents. Additional antibacterial, antiviral and antiparasitic effects are being studied. Artemisinin-based combination therapies are established medicines, not ordinary supplements. Herbal preparations should not replace standardized malaria treatment because dose variability can promote treatment failure and resistance. World Health Organization: Guidelines for malaria.

Evidence interpretation

  • Clinical evidence: Effects have been studied in human participants, but usually for a specific preparation, route, dose and indication.
  • Preclinical evidence: Activity has mainly been demonstrated in cell culture, microbial cultures or animal models.
  • Anti-adhesive or probiotic activity: The product may reduce colonization or pathogen attachment without directly killing the microorganism.
  • Topical evidence: Results from topical use cannot be assumed to apply to an orally administered supplement.


Stroke, Cerebral Ischemic Stroke: Click to Expand ⟱
Ischemic stroke is also called brain ischemia and cerebral ischemia. Ischemia is the medical term for "lack of blood supply." Most ischemic strokes occur when an artery supplying the brain becomes blocked by a thrombus or embolus.

Important: Ischemic stroke must be distinguished from hemorrhagic stroke before antiplatelet, anticoagulant, thrombolytic, or potentially blood-thinning therapies are used. The compounds below include standard therapies, nutritional adjuncts, and experimental neuroprotective compounds. They do not all have equivalent levels of clinical evidence.

Quick Reference

Mechanism Top Compounds
Antiplatelet / secondary stroke prevention Aspirin, Panax notoginseng/PNS, Ginkgo biloba/EGb 761, Salvia miltiorrhiza
Antioxidant / glutathione / ROS control N-Acetylcysteine (NAC), Melatonin, CoQ10, EGCG, Curcumin, Quercetin
Mitochondrial protection Melatonin, CoQ10, Resveratrol, Citicoline
Anti-inflammatory / NF-κB / cytokines NAC, Melatonin, Curcumin, Luteolin, Baicalin
Membrane repair / cholinergic support Citicoline, Alpha-GPC
BBB / neurovascular protection Melatonin, Rosmarinic acid, Astragaloside IV
Nutritional deficiency / rehabilitation support Vitamin D3, Vitamin B12, Folate, Magnesium
Experimental ischemic neuroprotection Tocotrienols, Luteolin, Ferulic acid, Honokiol, Berberine, Huperzine A

Stroke/Product Table - Dose + Clinical Translation Potential

Compound Class Primary Mechanisms Key Stroke Effects Evidence Level Phase Utility Human / Preclinical Dose Context Clinical Translation Potential
Aspirin / ASA NSAID / antiplatelet drug Irreversible COX-1 inhibition; ↓ thromboxane A2; ↓ platelet aggregation Reduces recurrent ischemic stroke risk in appropriate non-cardioembolic ischemic stroke patients Strong clinical; standard of care Acute after hemorrhage is excluded + secondary prevention Common long-term antiplatelet dose: approximately 75–100 mg/day; higher doses may be used in specific clinical circumstances High; established benefit, but bleeding-risk limited
N-Acetylcysteine (NAC) Thiol antioxidant / glutathione precursor ↑ glutathione; ↓ ROS; ↓ lipid peroxidation; anti-inflammatory effects; thiol/disulfide modulation; possible reduction of large VWF multimers Preliminary human evidence for improved neurological and functional recovery; reduction of oxidative and inflammatory biomarkers; possible antithrombotic/VWF effects Randomized human pilot studies + strong preclinical evidence Acute / early recovery No established routine post-stroke supplement dose. One clinical study used a 4 g loading dose followed by 4 g/day divided for 2 days; this is a research protocol, not a routine self-treatment dose Moderate–High; promising human evidence but not standard therapy
Melatonin Indoleamine / neurohormone ↓ ROS; mitochondrial protection; ↓ neuroinflammation; ↓ apoptosis; ↓ excitotoxicity; BBB protection; possible ↓ MMP-9 and NLRP3 signaling Reduced ischemia-reperfusion injury in experimental models; preliminary human evidence suggests improved neurological and functional recovery Preliminary randomized clinical + extensive preclinical evidence Acute + recovery; sleep/circadian support No established stroke-treatment dose. Low-dose sleep supplementation is commonly approximately 0.3–2 mg at night, while stroke trials have used study-specific pharmacological protocols Moderate–High; favorable safety profile at conventional doses, promising but unproven stroke efficacy
Vitamin D3 Vitamin / secosteroid hormone precursor Immune modulation; neurotrophic support; muscle function; vascular/endothelial support; calcium homeostasis May improve neurological and functional rehabilitation outcomes, particularly in vitamin-D-deficient patients Clinical studies + systematic review/meta-analysis; mixed but positive signal Recovery / deficiency correction Dose should be based on serum 25-OH-vitamin D status; no universal stroke-specific dose Moderate–High when deficient
Hydrogen Gas / Molecular Hydrogen Therapeutic medical gas ↓ ischemia/reperfusion oxidative stress; ↓ neuroinflammation; mitochondrial protection; ↓ apoptosis; BBB protection Potential reduction of secondary neuronal injury and improvement in early neurological recovery Small human RCT + substantial preclinical evidence Primarily acute / early recovery Clinical stroke study: 3% H₂ inhalation, 1 h twice daily for 7 days Promising but experimental; chronic rehabilitation benefit unproven
Coenzyme Q10 / CoQ10 Mitochondrial cofactor / antioxidant Supports mitochondrial electron transport; ↓ ROS; ↑ antioxidant capacity; anti-inflammatory effects Human studies suggest reductions in oxidative stress and inflammatory biomarkers after ischemic stroke; possible neurological benefit Small randomized human trials + preclinical evidence Acute + recovery Study-specific; no established post-stroke therapeutic dose. Common supplement doses are approximately 100–300 mg/day Moderate; encouraging human evidence but not standard therapy
Ginkgo biloba / EGb 761 Standardized herbal extract Cerebral microcirculation; antioxidant effects; platelet-activating-factor modulation; neuroprotection May support post-stroke cognition and neurological recovery; not established for prevention of recurrent stroke Clinical + preclinical; evidence stronger for standardized EGb 761 Recovery / cognition Approximately 120–240 mg/day standardized extract in many neurological studies Moderate; bleeding interaction caution, especially with antiplatelet or anticoagulant drugs
Panax notoginseng / PNS Triterpene saponins Anti-inflammatory; vascular/endothelial protection; microcirculation support; antiplatelet/antithrombotic effects; antioxidant activity Improved neurological and blood-flow outcomes in some clinical studies; much evidence involves standardized PNS or Xuesaitong preparations Clinical mainly from China + substantial preclinical evidence Acute + recovery Highly formulation-dependent; standardized extracts and injectable preparations cannot be directly equated with ordinary root supplements Moderate; possible bleeding interaction
Alpha-GPC / Alpha-glycerylphosphorylcholine Choline donor / phospholipid precursor ↑ acetylcholine; phosphatidylcholine synthesis; neuronal membrane support May support cognitive and neurological recovery after stroke Older human clinical evidence; modern confirmation limited Recovery / cognition Approximately 300–1200 mg/day in supplement/clinical use; no established modern stroke-treatment dose Moderate; possible TMAO/cardiovascular concern remains uncertain
Citicoline / CDP-choline Choline donor / phospholipid precursor ↑ phosphatidylcholine synthesis; membrane repair; ↓ free fatty acid release; cholinergic support Strong mechanistic rationale and possible cognitive effects, but no demonstrated benefit in the large ICTUS acute-stroke trial Clinical; large pivotal RCT negative, smaller/earlier studies mixed Recovery / cognition Approximately 500–2000 mg/day has been studied; no established effective post-stroke dose Low–Moderate efficacy / good tolerability
Salvia miltiorrhiza / Danshen Herbal extract Microcirculation; endothelial protection; antioxidant effects; antiplatelet activity May support cerebral perfusion and neurological recovery; evidence often involves Chinese standardized or injectable preparations Clinical mainly China + preclinical Acute + recovery Variable and formulation-dependent; no established dose for ordinary oral supplements after stroke Moderate; bleeding and drug-interaction caution
Vitamin B12 + Folate + Vitamin B6 B vitamins / methylation cofactors ↓ homocysteine; methylation support; endothelial and neurological function Potential secondary-prevention relevance when homocysteine is elevated or B12/folate deficiency is present Human clinical; mixed overall, stronger rationale in selected patients Prevention / recovery / deficiency correction Dose should be guided by B12, folate, renal function, and homocysteine status Moderate when indicated
Magnesium Essential mineral NMDA modulation; vascular tone; blood-pressure regulation; neuronal membrane stabilization Supports normal vascular and neurological function; direct therapeutic benefit after established stroke remains uncertain Nutritional/epidemiological support; limited treatment evidence Prevention / recovery / deficiency correction Prefer dietary adequacy and correction of deficiency; no established post-stroke therapeutic supplement dose Moderate when deficient
Omega-3 / EPA / DHA Marine fatty acids Lipid modulation; endothelial effects; inflammation modulation; membrane support Cardiovascular risk-factor support, but ordinary fish-oil supplementation has not consistently reduced recurrent stroke Human clinical; mixed for stroke-specific outcomes Prevention / long-term vascular health Prefer dietary fish intake; supplemental dose should be individualized, especially when combined with antithrombotic drugs Moderate for cardiovascular support; Low–Moderate for stroke-specific benefit
Baicalin Flavonoid Anti-inflammatory; anti-apoptotic; antioxidant; PI3K/Akt and related signaling Reduced neuronal injury, inflammation, and infarct size in experimental ischemia models Preclinical + limited clinical context Experimental acute neuroprotection No established human stroke dose Low–Moderate
Curcumin Polyphenol ↓ NF-κB; ↓ inflammatory cytokines; Nrf2 activation; antioxidant and anti-apoptotic effects Reduced infarct size, oxidative stress, and neuroinflammation in experimental ischemia models Strong preclinical; limited direct human stroke evidence Experimental acute + recovery General supplement doses commonly approximately 500–2000 mg/day depending on formulation; no established stroke dose Low–Moderate; bioavailability and bleeding-interaction considerations
Resveratrol Polyphenol SIRT1 activation; mitochondrial protection; antioxidant; anti-inflammatory; anti-apoptotic Reduced apoptosis and ischemic brain injury in experimental models Strong preclinical; limited direct clinical stroke evidence Experimental acute + recovery General supplement doses approximately 100–500 mg/day; no established stroke-treatment dose Low–Moderate; low bioavailability
EGCG Green-tea catechin ROS modulation; Nrf2-related antioxidant activity; vascular and mitochondrial protection Reduced neuronal injury and oxidative stress in experimental models Strong preclinical; little direct human stroke evidence Experimental acute neuroprotection Approximately 200–400 mg/day supplemental EGCG is commonly used; no established stroke dose Low–Moderate; hepatotoxicity risk increases with high-dose extracts
Quercetin Flavonoid Antioxidant; anti-inflammatory; anti-edema; endothelial protection Reduced edema, oxidative injury, and infarct size in experimental ischemia models Strong preclinical; limited direct clinical stroke evidence Experimental acute neuroprotection Approximately 500–1000 mg/day commonly used as a supplement; no established stroke dose Low–Moderate
Tocotrienols Vitamin E subfamily Lipid antioxidant; membrane protection; anti-inflammatory and neuroprotective signaling Neuroprotection and reduced ischemic injury in experimental models Preclinical + limited human neurological evidence Experimental acute / prevention Approximately 100–300 mg/day commonly used in supplements; no established stroke dose Low–Moderate
Luteolin Flavonoid ↓ NF-κB; Nrf2 activation; PI3K/Akt modulation; anti-inflammatory; anti-apoptotic effects Reduced inflammation and neuronal injury in experimental stroke models Strong preclinical Experimental acute neuroprotection No established human stroke dose Low
Ferulic acid Phenolic acid Antioxidant; vasodilation; endothelial and vascular protection Improved cerebral blood flow and reduced neuronal injury in experimental models Preclinical Experimental acute neuroprotection No established human stroke dose Low
Rosmarinic acid Phenolic acid BBB protection; antioxidant; anti-inflammatory; anti-apoptotic Reduced BBB disruption, edema, and inflammatory injury in experimental ischemia models Preclinical Experimental acute neuroprotection No established human stroke dose Low
Berberine Isoquinoline alkaloid AMPK activation; metabolic regulation; anti-inflammatory, antioxidant, and endothelial effects Neuroprotection in experimental ischemia; may also improve metabolic vascular risk factors Predominantly preclinical for stroke Prevention + experimental recovery Approximately 500–1500 mg/day commonly used metabolically; no established stroke-treatment dose Low–Moderate; substantial drug-interaction potential
Huperzine A Alkaloid / acetylcholinesterase inhibitor AChE inhibition; ↑ acetylcholine; possible NMDA modulation and neuroprotection Potential support for post-stroke cognitive dysfunction, but direct clinical evidence is limited Preclinical + indirect cognitive clinical evidence Experimental recovery / cognition Approximately 100–200 µg/day commonly used; no established stroke-treatment dose Low; cholinergic adverse effects may limit use
Honokiol Biphenolic lignan Mitochondrial protection; antioxidant; anti-inflammatory; anti-apoptotic effects Reduced ischemic neuronal injury in experimental models Preclinical Experimental acute + recovery No established human stroke dose Low

Evidence interpretation:
Strong clinical = established benefit supported by major clinical trials and/or treatment guidelines.
Human clinical / preliminary clinical = human studies exist, but evidence is not sufficient to establish routine stroke therapy.
Preclinical = evidence is predominantly from cell culture or animal ischemia models and should not be assumed to translate into clinical benefit.

Dose interpretation:
Human supplement doses shown above are general clinical or supplemental dose ranges unless specifically identified as a stroke-study protocol. They should not be interpreted as established doses for acute ischemic stroke treatment.

Drug-interaction caution:
Compounds with antiplatelet, anticoagulant, or vascular effects—including Ginkgo biloba, Panax notoginseng, Salvia miltiorrhiza, curcumin, high-dose omega-3, and potentially NAC—may interact with aspirin, clopidogrel, warfarin, DOAC anticoagulants, thrombolytic therapy, or other antithrombotic treatments.

HED: Human Equivalent Dose. HED should refer specifically to translation of an animal dose to an estimated human dose, usually using body-surface-area scaling. A measured human dose divided by body weight is not an HED.
Scientific Papers found: Click to Expand⟱
6556- BSB,    A Comprehensive Study of Therapeutic Applications of Chamomile
- Review, Nor, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, *antiOx↑, *AntiBio↑, *hepatoP↑, *AntiCan↑, *other↝, *toxicity↓, *Wound Healing↓, *Dose↝, *Dose↝, *eff↝, *ROS↓, *TNF-α↓, *IL6↓, *other↝, *AST↓, *ALAT↓,
7260- Gink,    Ginkgetin: A natural biflavone with versatile pharmacological activities
- Review, Var, NA - Review, Stroke, NA - Review, AD, NA
*AntiCan↑, *Inflam↓, *AntiBio↑, *neuroP↑, *TumCCA↑, Apoptosis↑, TumAuto↑, iNOS↓, COX2↓, PGE2↓, NF-kB↓, PLA2↓, *neuroP↑, *Stroke↓, *AntiFungal↓, *Bacteria↓, Bcl-xL↓, Bcl-2↓, Casp9↑, Casp3↑, cl‑PARP↑, IL6↓, STAT3↓, JAK1↓, survivin↓, COX2↓, IAP1↓, MMP2↓, MMP9↓, PTEN↑, SHP1↑, eff↑, TumVol↓, TumW↓, *toxicity↓, *ROS↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

PLA2↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp3↑, 1,   Casp9↑, 1,   IAP1↓, 1,   iNOS↓, 1,   survivin↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PTEN↑, 1,   SHP1↑, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   MMP9↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   IL6↓, 1,   JAK1↓, 1,   NF-kB↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 1,   TumW↓, 1,  
Total Targets: 25

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 2,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ROS↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,   eff↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   hepatoP↑, 1,   neuroP↑, 2,   toxicity↓, 2,   Wound Healing↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↓, 1,   Bacteria↓, 1,  
Total Targets: 22

Scientific Paper Hit Count for: AntiBio, Antibiotic/Antimicrobial activity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:36  Cells:%  prod#:%  Target#:1483  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page